{
    "title": "Individual feed for http://feeds.benzinga.com/benzinga",
    "link": "http://feeds.benzinga.com/benzinga",
    "description": "Individual feed output.",
    "lastBuildDate": "2025-08-01T10:56:32.147970",
    "items": [
        {
            "title": "Celestica, Inc. (CLS) is Attracting Investor Attention: Here is What You Should Know",
            "link": "https://www.benzinga.com/node/46796656",
            "description": "Celestica (NYSE: CLS ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factor...",
            "pubDate": "2025-08-01T15:33:23",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture7.png"
        },
        {
            "title": "$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today",
            "link": "https://www.benzinga.com/insights/news/25/08/46796428/1000-invested-in-this-stock-5-years-ago-would-be-worth-this-much-today",
            "description": "read more",
            "pubDate": "2025-08-01T15:30:26",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture4.png"
        },
        {
            "title": "4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study",
            "link": "https://www.benzinga.com/news/health-care/25/08/46796384/4d-molecular-therapeutics-rallies-on-heels-of-diabetes-related-vision-study",
            "description": "4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment. read more",
            "pubDate": "2025-08-01T15:29:21",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/08/01/Macro-Photo-Of-Woman-With-Beautiful-Eyes.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        },
        {
            "title": "LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People",
            "link": "https://www.benzinga.com/news/fda/25/08/46796085/lenz-therapeutics-eye-drop-scores-first-fda-approval-for-age-related-blurred-vision-condition-impacting-",
            "description": "LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025. read more",
            "pubDate": "2025-08-01T15:25:51",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/08/01/Presbyopia-eye-condition.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        },
        {
            "title": "Exxon Mobil Hits Record Production, CEO Reaffirms Hunt For Value-Driven Deals",
            "link": "https://www.benzinga.com/markets/earnings/25/08/46795989/exxon-mobil-hits-record-production-ceo-reaffirms-hunt-for-value-driven-deals",
            "description": "Exxon Mobil Corp. (XOM) Q2 earnings beat estimates with $7.1B profit on record production and revenues, plans for growth and acquisitions. read more",
            "pubDate": "2025-08-01T15:22:51",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/08/01/Trinidad--Co--Usa---May-19--2024-Exxon-G.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        }
    ]
}